Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Blood pressure (BP) control is a key therapeutic intervention in chronic kidney disease (CKD) but patients find meeting BP targets challenging. The SMaRT BP CKD trial aimed to assess the feasibility of supported self-management of BP for people with CKD in secondary care using an approach previously trialled successfully in primary care. In addition to the main trial, semi-structured interviews were conducted with participants to evaluate barriers and facilitators to adopting the intervention.
SMaRT BP CKD was a single centre randomised feasibility trial of a self-management intervention with home BP monitoring monthly alongside research team supported escalation of anti-hypertensive treatment. Inclusion criteria were: CKD stages 1-4, aged >18years, prescribed <4 anti-hypertensive agents and an average clinic BP in the preceding 12 months of >120mmHg, or >130mmHg systolic if they had diabetes. Participants were recruited from CKD outpatient clinics and were randomised 1:1 to intervention or standard care. Those in the intervention arm of the study were invited to participate in a semi-structured interview after at least six months of the intervention or upon withdrawal from the study. Interviews were conducted by telephone or in person and were intended to explore barriers and facilitators to adopting the intervention. They were recorded and transcribed verbatim. Transcripts were imported into nVivo software and analysed using a thematic analysis (TA) approach.
Thirteen interviews were conducted between February 2024 and August 2025 from a total of 23 participants in the intervention group. The median (IQR) age was 75 (65-81), the majority of participants interviewed were male (77%). At baseline the interview cohort had a median eGFR of 33 (29-53)ml/min/1.73m2, uACR of 9.4 (3-36.5)mg/mmol. Baseline median systolic and diastolic BP was 141 (133-147) mmHg and 77 (65-88) mmHg. At 12 months the median systolic and diastolic BP for the cohort was 135 (132-143)mmHg and 77 (65-88)mmHg.
Initial TA identified themes reflecting key barriers and facilitators to adopting the self management intervention. Themes included: factors related to individual participants—such as beliefs about BP, CKD, and medication—as well as themes specific to the study procedures and intervention itself. These included challenges with BP monitoring equipment and time constraints as barriers to participation, and trust in the research team and affinity to the local renal unit maintaining participation.
The interviews provided in-depth data from participants on factors influencing their adoption of the self management intervention for BP control in the SMaRT BP CKD feasibility trial. Potential approaches to improving adoption of the self-management intervention include the development of targeted educational resources to address common misconceptions, use of automated prompts for home BP monitoring and assessing individual readiness to self-manage anti-hypertensive medications
